Literature DB >> 27241718

Histone H3 acetylation in the postmortem Parkinson's disease primary motor cortex.

Kibrom G Gebremedhin1, David J Rademacher2.   

Abstract

Although the role of epigenetics in Parkinson's disease (PD) has not been extensively studied, α-synuclein, the main component of Lewy bodies, decreased histone H3 acetylation. Here, we determined if there were histone acetylation changes in the primary motor cortex which, according to the Braak model, is one of the last brain regions affected in PD. Net histone H3 acetylation, histone H3 lysine 9 (H3K9), histone H3 lysine 14 (H3K14), histone H3 lysine 18 (H3K18), and histone H3 lysine 23 (H3K23) acetylation was assessed in the primary motor cortex of those affected and unaffected by PD. There was net increase in histone H3 acetylation due to increased H3K14 and H3K18 acetylation. There was a decrease in H3K9 acetylation. No between-groups difference was detected in H3K23 acetylation. Relationships between Unified Lewy Body Staging scores and histone H3 acetylation and substantia nigra depigmentation scores and histone H3 acetylation were observed. No relationships were detected between postmortem interval and histone H3 acetylation and expired age and histone H3 acetylation. These correlational data support the notion that the histone H3 acetylation changes observed here are not due to the postmortem interval or aging. Instead, they are due to PD and/or factors that covary with PD. The data suggest enhanced gene transcription in the primary motor cortex of the PD brain due to increase H3K14 and H3K18 acetylation. This effect is partially offset by a decreased H3K9 acetylation, which might repress gene transcription.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Epigenetics; Gene transcription; Histone acetylation; Lysine residues; Parkinson’s disease; Unified Lewy Body staging

Mesh:

Substances:

Year:  2016        PMID: 27241718      PMCID: PMC5067161          DOI: 10.1016/j.neulet.2016.05.060

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  31 in total

1.  Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms.

Authors:  Takuma Uo; Timothy D Veenstra; Richard S Morrison
Journal:  J Neurosci       Date:  2009-03-04       Impact factor: 6.167

Review 2.  Histone acetylation in chromatin structure and transcription.

Authors:  M Grunstein
Journal:  Nature       Date:  1997-09-25       Impact factor: 49.962

Review 3.  The inheritance of epigenetic defects.

Authors:  R Holliday
Journal:  Science       Date:  1987-10-09       Impact factor: 47.728

4.  Patterns of histone acetylation.

Authors:  A W Thorne; D Kmiciek; K Mitchelson; P Sautiere; C Crane-Robinson
Journal:  Eur J Biochem       Date:  1990-11-13

5.  Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease.

Authors:  Wenbo Zhou; Kathryn Bercury; Jessica Cummiskey; Nancy Luong; Jacob Lebin; Curt R Freed
Journal:  J Biol Chem       Date:  2011-03-03       Impact factor: 5.157

6.  Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity.

Authors:  Eirene Kontopoulos; Jeffrey D Parvin; Mel B Feany
Journal:  Hum Mol Genet       Date:  2006-09-07       Impact factor: 6.150

7.  Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity.

Authors:  Gabriella Gardian; Lichuan Yang; Carine Cleren; Noel Y Calingasan; Peter Klivenyi; M Flint Beal
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

8.  Lewy bodies in Betz cells of the motor cortex in a patient with Parkinson's disease.

Authors:  Koichi Wakabayashi; Fumiaki Mori; Yoshinobu Oyama; Aiichiro Kurihara; Mitsuru Kamada; Makoto Yoshimoto; Hitoshi Takahashi
Journal:  Acta Neuropathol       Date:  2002-10-23       Impact factor: 17.088

Review 9.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.

Authors:  Dennis W Dickson; Heiko Braak; John E Duda; Charles Duyckaerts; Thomas Gasser; Glenda M Halliday; John Hardy; James B Leverenz; Kelly Del Tredici; Zbigniew K Wszolek; Irene Litvan
Journal:  Lancet Neurol       Date:  2009-12       Impact factor: 44.182

10.  Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons.

Authors:  Xuefei Wu; Po See Chen; Shannon Dallas; Belinda Wilson; Michelle L Block; Chao-Chuan Wang; Harriet Kinyamu; Nick Lu; Xi Gao; Yan Leng; De-Maw Chuang; Wanqin Zhang; Ru Band Lu; Jau-Shyong Hong
Journal:  Int J Neuropsychopharmacol       Date:  2008-07-09       Impact factor: 5.176

View more
  14 in total

Review 1.  The impact of histone post-translational modifications in neurodegenerative diseases.

Authors:  Samantha N Cobos; Seth A Bennett; Mariana P Torrente
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-10-20       Impact factor: 5.187

2.  Acute Hypoxia and Chronic Ischemia Induce Differential Total Changes in Placental Epigenetic Modifications.

Authors:  Adrian C Eddy; Heather Chapman; Eric M George
Journal:  Reprod Sci       Date:  2018-09-17       Impact factor: 3.060

3.  Molecular insights into α-synuclein interaction with individual human core histones, linker histone, and dsDNA.

Authors:  Sneha Jos; Hemanga Gogoi; Thazhe Kootteri Prasad; Manjunath A Hurakadli; Neelagandan Kamariah; Balasundaram Padmanabhan; Sivaraman Padavattan
Journal:  Protein Sci       Date:  2021-08-19       Impact factor: 6.993

Review 4.  The Role of DNA Methylation and Histone Modifications in Neurodegenerative Diseases: A Systematic Review.

Authors:  Ke-Xin Wen; Jelena Miliç; Bassem El-Khodor; Klodian Dhana; Jana Nano; Tammy Pulido; Bledar Kraja; Asija Zaciragic; Wichor M Bramer; John Troup; Rajiv Chowdhury; M Arfam Ikram; Abbas Dehghan; Taulant Muka; Oscar H Franco
Journal:  PLoS One       Date:  2016-12-14       Impact factor: 3.240

Review 5.  The class II histone deacetylases as therapeutic targets for Parkinson's disease.

Authors:  Martina Mazzocchi; Louise M Collins; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Neuronal Signal       Date:  2020-06-09

Review 6.  Epigenetics in Lewy Body Diseases: Impact on Gene Expression, Utility as a Biomarker, and Possibilities for Therapy.

Authors:  Aintzane Urbizu; Katrin Beyer
Journal:  Int J Mol Sci       Date:  2020-07-02       Impact factor: 5.923

Review 7.  Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy.

Authors:  Donglu Wu; Ye Qiu; Yunshuang Jiao; Zhidong Qiu; Da Liu
Journal:  Front Oncol       Date:  2020-11-11       Impact factor: 6.244

Review 8.  Epigenetic Regulation of Neuroinflammation in Parkinson's Disease.

Authors:  Madiha Rasheed; Junhan Liang; Chaolei Wang; Yulin Deng; Zixuan Chen
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

9.  Histone acetylation as a new mechanism for bilirubin-induced encephalopathy in the Gunn rat.

Authors:  Eleonora Vianello; Stefania Zampieri; Thomas Marcuzzo; Fabio Tordini; Cristina Bottin; Andrea Dardis; Fabrizio Zanconati; Claudio Tiribelli; Silvia Gazzin
Journal:  Sci Rep       Date:  2018-09-12       Impact factor: 4.379

Review 10.  Imbalance of Lysine Acetylation Contributes to the Pathogenesis of Parkinson's Disease.

Authors:  Rui Wang; Hongyang Sun; Guanghui Wang; Haigang Ren
Journal:  Int J Mol Sci       Date:  2020-09-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.